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Objectives The aim of this study was to compare outcomes in patients receiving consistent unfractionated heparin (UFH)/
enoxaparin (ENOX) therapy and in those switched at randomization to bivalirudin monotherapy.
Background Crossover between UFH and ENOX has been associated with increased adverse outcomes in patients with acute
coronary syndromes. The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial demon-
strated superior net clinical outcomes with similar rates of ischemia and significantly less major bleeding with
bivalirudin monotherapy compared with UFH/ENOX plus a glycoprotein (GP) IIb/IIIa inhibitor. It is unknown if
these results would be preserved in patients switched from UFH/ENOX to bivalirudin monotherapy.
Methods We compared composite ischemia, major bleeding, and net clinical outcomes at 30 days in patients receiving
consistent UFH/ENOX therapy and in those switched at randomization from pre-treatment with UFH/ENOX to
bivalirudin monotherapy. We also compared outcomes in patients naive to antithrombin therapy who were ran-
domized to UFH/ENOX or bivalirudin monotherapy.
Results Two thousand one hundred thirty-seven patients received consistent UFH/ENOX (UFH n  1,294, ENOX n 
843), and 2,078 patients pre-treated with UFH/ENOX were switched to bivalirudin. Patients switching to bivaliru-
din had similar rates of ischemia (6.9% vs. 7.4%, p  0.52), less major bleeding (2.8% vs. 5.8%, p  0.01), and
improved net clinical outcomes (9.2% vs. 11.9%, p  0.01) than those on consistent UFH/ENOX plus a GP IIb/
IIIa inhibitor. Patients naive to antithrombin therapy who were administered bivalirudin (n  1,427) had similar
rates of ischemia (6.2% vs. 5.5%, p  0.47), less major bleeding (2.5% vs. 4.9%, p  0.001), and similar net
clinical outcomes (8.0% vs. 9.4%, p  0.17) compared with naive patients administered UFH/ENOX plus a GP
IIb/IIIa inhibitor (n  1,462).
Conclusions Switching from UFH/ENOX to bivalirudin monotherapy results in comparable ischemic outcomes and an approxi-
mately 50% reduction in major bleeding compared with consistent UFH/ENOX plus a GP IIb/IIIa inhibitor. Pa-
tients naive to antithrombin therapy administered bivalirudin monotherapy had a significant reduction in bleed-
ing and similar rates of ischemia compared with naive patients initiated with UFH or ENOX plus a GP IIb/IIIa
inhibitor. (J Am Coll Cardiol 2008;51:1734–41) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.052
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May 6, 2008:1734–41 Safety of Switching From Heparin to Bivalirudinptimal management for moderate- and high-risk patients
ith non–ST-segment elevation acute coronary syndromes
NSTE-ACS) includes an invasive strategy with intensive
ntithrombin therapy (1). Most patients with acute coronary
yndromes are currently treated with either unfractionated
eparin (UFH) or enoxaparin (ENOX) initiated either in the
mergency department or in a transferring hospital before
oronary intervention. In recent clinical trials, such as the
YNERGY (Superior Yield of the New Strategy of ENOX,
evascularization and Glycoprotein IIb/IIIa Inhibitors) trial
2) and the OASIS-5 (Organization to Assess Strategies for
schemic Syndromes) trial (3), 72% and 50% of patients,
espectively, received clinician-selected antithrombin treat-
ent before randomization. It is of note, however, that
ransitions from an upstream heparin to an alternate heparin
ave been associated with an increase in adverse clinical
utcomes. In the SYNERGY trial, patients who crossed
ver after randomization from UFH to ENOX or vice versa
ad increased rates of death/myocardial infarction (MI)
ithin 30 days compared with those who did not cross over
22.0% vs. 14.2%, UFH; 17.4% vs. 13.5%, ENOX). The
ate of transfusion doubled with crossover (35% vs. 15.1%,
FH; 30.2% vs. 15.3%, ENOX) (4). However, because
hese crossovers occurred after randomization, association or
ausality cannot be defined. Patients may have crossed over
ue to ischemia or bleeding, or, alternatively, crossing over
ay have caused an ischemic or bleeding event (2). Con-
istent therapy, however, was associated with lower rates of
eath/MI (5). Consistent antithrombin therapy has been
ecommended in guidelines while changing therapy has
een discouraged (6).
The ACUITY (Acute Catheterization and Urgent Inter-
ention Triage strategY) trial (7) demonstrated that, in patients
ith moderate- and high-risk NSTE-ACS, treatment with
ivalirudin monotherapy resulted in similar rates of composite
schemia, a 47% relative (2.7% absolute) reduction in major
leeding, and improved net clinical outcomes compared with
reatment with UFH/ENOX plus a glycoprotein (GP) IIb/
IIa inhibitor. In light of recent data indicating an association
etween bleeding and mortality (8,9), these results suggest that
ivalirudin is an attractive alternative for patients with NSTE-
CS (8). It is unknown, however, if the results observed in the
verall trial would be preserved in the subgroup of patients
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ew Zealand; †Department of Cardiology, Flinders Medical Centre, Adelaide,
ustralia; ‡Department of Emergency Medicine, Wake Forest University Health
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niversity of Pennsylvania Health System, Philadelphia, Pennsylvania; New York
niversity School of Medicine, New York, New York; ¶Department of Cardiovas-
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ute, Lille, France; **London School of Hygiene and Tropical Medicine, London,
nited Kingdom; ††Harvard School of Public Health, Boston, Massachusetts;
‡Duke University Medical Center, Durham, North Carolina; §§Department of
edicine, Columbia University Medical Center, New York, New York; and the
Cardiovascular Research Foundation, New York, New York. For full author
isclosures, please see the end of this paper.u
Manuscript received September 12, 2007; revised manuscript received December
3, 2007, accepted December 17, 2007.re-treated with either UFH or
NOX before randomization and
hen switched to bivalirudin mono-
herapy. In the present analysis of
he ACUITY trial, we sought to
etermine whether patients could
e safely switched from UFH or
NOX to bivalirudin.
ethods
n the ACUITY trial, 13,819 pa-
ients with moderate- and high-
isk NSTE-ACS were random-
zed to receive either UFH or
NOX plus GP IIb/IIIa inhibi-
ors or bivalirudin monotherapy
ith provisional use of GP IIb/
IIa inhibitors for ischemic complications (7). Entry criteria
ave been previously described in detail (10). In brief,
atients18 years of age with symptoms of unstable angina
asting 10 min within the preceding 24 h were eligible for
nrollment if 1 or more of the following criteria were met:
ew ST-segment depression or transient elevation 1 mm;
roponin I, troponin T, or creatine kinase-MB elevation;
nown coronary artery disease; or all 4 other Thrombolysis
n Myocardial Infarction unstable angina risk criteria (11)
ositive. Enrollment of patients treated with UFH or a
ingle dose of low-molecular-weight heparin before ran-
omization was permitted. Major exclusion criteria included
cute ST-segment elevation MI or shock; bleeding diathesis
r major bleed within 2 weeks; or thrombocytopenia or
alculated creatinine clearance 30 ml/min. The study was
pproved by the institutional review board or ethics com-
ittee at each participating center, and all patients signed
ritten, informed consent.
andomization and study protocol. Patients were as-
igned by a primary randomization to 1 of 3 antithrombin
egimens started before angiography: heparin (either unfrac-
ionated or ENOX at site discretion) plus glycoprotein (GP)
Ib/IIIa inhibitors, bivalirudin (intravenous bolus of 0.1
g/kg and an infusion of 0.25 mg/kg/h, with an additional
olus 0.5 mg/kg and an increased infusion rate of 1.75
g/kg/h if the patient continued on to percutaneous coro-
ary intervention [PCI]) plus GP IIb/IIIa inhibitors, or
ivalirudin monotherapy, with GP IIb/IIIa inhibitors re-
erved for ischemic complications. The heparin dosing
egimens have been previously described (10). Patients
ssigned to heparin plus a GP IIb/IIIa inhibitor or bivaliru-
in plus a GP IIb/IIIa inhibitor were randomized again in
2  2 factorial design to upstream GP IIb/IIIa inhibitor
nitiation in all patients immediately after randomization
ersus deferred GP IIb/IIIa inhibitor initiation for selective
se starting in the catheterization laboratory in patients
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
ENOX  enoxaparin
GP  glycoprotein
MI  myocardial infarction
NSTE-ACS  non–ST-
segment elevation acute
coronary syndromes
PCI  percutaneous
coronary intervention
RR  relative risk
UFH  unfractionated
heparinndergoing PCI.
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Safety of Switching From Heparin to Bivalirudin May 6, 2008:1734–41Angiography was planned, by protocol, in all patients
ithin 72 h after randomization. Patients then underwent
ither PCI, coronary artery bypass grafting (CABG), or
edical management per physician discretion. Aspirin 300
o 325 mg orally or 250 to 500 mg intravenously was
dministered daily during the index hospitalization, and 75
o 325 mg daily was prescribed indefinitely after discharge.
he choice to administer clopidogrel as well as its initial
osing and timing were left to investigator discretion per
ocal standards, though a 300-mg or greater loading dose
as required in all cases no later than 2 h after PCI.
lopidogrel 75 mg daily was strongly recommended for 1
ear in all patients with coronary artery disease.
Initially, all patients in the control arm were assigned to
NOX only, but after release of the SYNERGY trial results
he protocol was amended so that the control arm included
oth UFH and ENOX (12). Investigators at each site were
equired to prospectively declare and utilize a single pre-
erred heparin agent (UFH or ENOX) for all patients unless
patient had been previously started on the alternate
ntithrombin agent, in which case the principle of main-
aining consistent therapy applied. Switching between UFH
nd ENOX was not permitted. Patients receiving UFH
efore randomization who were switched to bivalirudin at
andomization were required to wait 30 min before admin-
stration of bivalirudin. Patients receiving a single dose of
NOX who were switched to bivalirudin were required to
ait 8 h before administration of bivalirudin.
Figure 1 Flow of ACUITY Trial and Patients Switched
Enrollment and randomization to consistent therapy, either unfractionated heparin
from either UFH or Enox. Naive patients are those who received no antithrombin th
randomization drug; the administration of the randomization drug was after angiog
eterization and Urgent Intervention Triage strategY; GP  glycoprotein.Three primary end points at 30 days were analyzed:
omposite ischemia (death, MI, or unplanned revascular-
zation for ischemia), non-CABG major bleeding, and net
linical outcome composed of composite ischemia or non-
ABG major bleeding. Noncoronary artery bypass grafting
ajor bleeding was defined as intracranial bleeding or
ntraocular bleeding, retroperitoneal bleeding, access site
leed resulting in a hematoma 5 cm or requiring inter-
ention/surgery, Hgb decrease by 3 g/dl with an overt
ource or by 4 g/dl without an overt source, any blood
roduct transfusion, or reoperation for bleeding. All primary
nd points were adjudicated by a blinded clinical events
ommittee.
To evaluate the safety of switching to bivalirudin after
re-treatment with UFH or ENOX before randomization,
e compared ischemic and bleeding outcomes in patients
aintained on consistent UFH/ENOX with those for
atients switched to bivalirudin monotherapy. We defined
witching as a protocol-defined activity driven by random-
zation. Patients were defined as being on consistent therapy
f their randomized antithrombin was the same as their
re-randomization antithrombin; patients were defined as
aving been switched if after receiving either UFH or
NOX before randomization they were subsequently ran-
omized to bivalirudin monotherapy. In a separate explor-
tory analysis, we evaluated ischemic and bleeding outcomes
y treatment assignment in patients who were naive to
ntithrombin therapy at the time of randomization (Fig. 1).
atients with high-risk features (defined as elevated cardiac
or enoxaparin (Enox), or switch (at the time of randomization) to bivalirudin (Biv)
before randomization. *Patients were also excluded if they did not receive the
or they received both UHF and Enox before randomization. ACUITY  Acute Cath-(UFH)
erapy
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May 6, 2008:1734–41 Safety of Switching From Heparin to Bivalirudiniomarkers or electrocardiographic changes at presentation)
s well as those triaged to a PCI strategy were also analyzed
ithin the groups of patients receiving prior antithrombin
herapy and those naive to antithrombin therapy.
tatistics. To compare baseline characteristics, the chi-
quare test was used for categorical variables and the
ilcoxon rank sum test was used for continuous variables.
edians and interquartile ranges (or ranges) are presented
or continuous variables. To evaluate potential dependencies
f the safety and efficacy of bivalirudin monotherapy relative
o UFH/ENOX on whether the patient was receiving
re-randomization antithrombin, interaction tests between
rior therapy (receiving or not receiving antithrombin ther-
py before randomized study drug) and treatment assign-
ent (UFH/ENOX vs. bivalirudin monotherapy) were
onducted. Relative risk (RR) was used to make compari-
ons among antithrombin therapy groups. The correspond-
ng confidence intervals (CIs) and p values were derived
sing normal approximation. A 2-sided value of   0.05
as used for all superiority testing. All analyses were
erformed using SAS version 9 (SAS Institute, Cary, North
arolina).
esults
tudy population. Of the 13,819 randomized patients,
,604 patients who were randomized to bivalirudin plus GP
Ib/IIIa inhibitors were excluded. The reason for excluding
aseline Characteristics
Table 1 Baseline Characteristics
Consistent Therapy
UFH/Enoxaparin 
GP IIb/IIIa Inhibitor
(n  2,137)
Switch to Bivalirud
(n  2,078)
Age, median (range), yrs 63.0 (23, 91) 62 (20, 9
Male gender 1,538 (72.0%) 1,459 (70.2
Weight, median (IQR), kg 84 (73, 96) 84 (73, 9
Diabetes 595/2,122 (28.0%) 536/2,063 (26.0
Hypertension 1,391/2,134 (65.2%) 1,337/2,070 (64.6
Hyperlipidemia 1,175/2,095 (56.1%) 1,131/2,034 (55.6
Current smoker 631/2,104 (30.0%) 635/2,051 (31.0
Prior MI 668/2,096 (31.9%) 627/2,033 (30.8
Prior PCI 799/2126 (37.6%) 770/2,062 (37.3
Prior CABG 402/2,135 (18.8%) 382/2,074 (18.4
Thienopyridine exposure 1,327/2,108 (63.0%) 1,342/2,072 (64.8
Renal insufficiency* 396/2,016 (19.6%) 344/1,989 (17.3
U.S. enrollment 1,180/2,137 (55.2%) 1,180/2,078 (56.8
High risk† 1,581/2,047 (77.2%) 1,496/2,024 (73.9
Troponin elevation 1,235/1,902 (64.9%) 1,188/1,883 (63.1
ST-segment deviation 748/2,136 (35.0%) 669/2,078 (32.2
TIMI risk score
0 to 2 310/1,879 (16.5%) 340/1,845 (18.4
3 to 4 990/1,879 (52.7%) 987/1,845 (53.5
5 to 7 579/1,879 (30.8%) 518/1,845 (28.1
Calculated creatinine clearance using the Cockcroft-Gault equation 60 ml/min; †elevated card
CABG  coronary artery bypass surgery; GP  glycoprotein; IQR  interquartile range; MI  my
ivalirudin versus consistent therapy unfractionated heparin/enoxaparin; P2  p value for comparison
yocardial Infarction; UFH  unfractionated heparin.hese patients is that in the overall ACUITY trial bivaliru-
in with GP IIb/IIIa inhibitors resulted in a similar rate of
schemic events as the UFH/ENOX  GP IIb/IIIa inhib-
tor arm (7.7% vs. 7.3%) and similar major bleeding rates
5.3% vs. 5.7%). Also excluded from the present analysis
ere 2,111 patients who either did not receive the random-
zation drug (n  324), who were administered the ran-
omization drug for the first time after angiography (n 
35), or who received both UFH and ENOX before or after
andomization (n  1,652). A total of 4,215 patients
eceived prior antithrombin therapy with either UFH or
NOX before randomization. Of these, 2,137 were ran-
omized to receive the same antithrombin plus a GP
Ib/IIIa inhibitor (consistent), while 2,078 patients were
andomized to receive bivalirudin (switch). There were
,889 patients naive to antithrombin therapy at randomiza-
ion, and, of these, 1,462 patients were randomized to
FH/ENOX plus a GP IIb/IIIa inhibitor and 1,427 to
ivalirudin monotherapy (Fig. 1). There were 351 patients
ho potentially may have been excessively dosed because of
ack of dose adjustment for renal dysfunction; creatinine
learance 30 ml/min for ENOX and 50 ml/min for
ptifibatide.
atients receiving prior antithrombin therapy. As shown
n Table 1, patients randomized to consistent UFH/ENOX
herapy were, on median, 1 year older than patients
witched to bivalirudin, though more patients switched to
ivalirudin had high-risk features (defined as elevated car-
P1
Naive
UFH/Enoxaparin 
GP IIb/IIIa Inhibitor
(n  1,462)
Naive Bivalirudin
(n  1,427) P2
0.03 63.0 (30, 91) 63.0 (25, 92) 0.69
0.21 973 (66.6%) 943 (66.1%) 0.79
0.22 84.0 (72, 95) 84.0 (73, 95) 0.49
0.13 432/1,453 (29.7%) 430/1,416 (30.4%) 0.71
0.69 1,013/1,453 (69.7%) 1,008/1,425 (70.7%) 0.55
0.76 889/1,446 (61.5%) 895/1,410 (63.5%) 0.27
0.50 384/1,437 (26.7%) 372/1,405 (26.5%) 0.88
0.48 455/1,424 (32.0%) 496/1,388 (35.7%) 0.03
0.87 675/1,453 (46.5%) 712/1,414 (50.4%) 0.04
0.73 292/1,458 (20.0%) 300/1,423 (21.1%) 0.48
0.22 927/1,443 (64.2%) 914/1,404 (65.1%) 0.63
0.06 247/1,376 (18.0%) 268/1,338 (20.0%) 0.17
0.30 982/1,462 (67.2%) 965/1,427 (67.6%) 0.79
0.01 805/1,345 (59.9%) 818/1,322 (61.9%) 0.28
0.24 486/1,172 (41.5%) 507/1,126 (45.0%) 0.09
0.05 453/1,461 (31.0%) 428/1,426 (30.0%) 0.56
0.11 0.23
192/1,272 (15.1%) 157/1,232 (12.7%)
731/1,272 (57.5%) 721/1,232 (58.5%)
349/1,272 (27.4%) 354/1,232 (28.7%)
markers or ST-segment deviation 1 mm.
l infarction; PCI  percutaneous coronary intervention; P1  p value for comparison for switch toin
2)
%)
6)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
%)
iac bio
ocardiafor naive bivalirudin versus naive unfractionated heparin/enoxaparin; TIMI  Thrombolysis In
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Safety of Switching From Heparin to Bivalirudin May 6, 2008:1734–41iac biomarkers or electrocardiogram changes at presenta-
ion); there were no other significant baseline demographic
ifferences. At 30 days, there was no difference in composite
schemia between the 2 groups: 6.9% for patients switched
o bivalirudin versus 7.4% for patients remaining on consis-
ent UFH/ENOX (RR 0.93; 95% CI 0.75 to 1.16, p 
.52). Major bleeding was significantly reduced by 51%:
.8% for patients switched to bivalirudin versus 5.8% for
atients remaining on consistent UFH/ENOX (RR 0.49;
5% CI 0.36 to 0.66, p  0.01). Transfusions were also
ower in the patients switched to bivalirudin versus patients
emaining on consistent UFH/ENOX (1.5% vs. 2.6% [RR
.60; 95% CI 0.39 to 0.92], p  0.02) (Table 2).
There were 181 patients on antithrombin therapy before
andomization who potentially were overdosed; eptifibatide
67, ENOX 12, and 2 both eptifibatide and ENOX. When
hese patients were excluded from analyses, the analyses for
schemic events were unchanged and major bleeding rates
or the consistent UFH or ENOX group were 5.6% versus
.8% for the bivalirudin group (RR 0.50, 95% CI 0.37 to 69,
 0.0001).
Net clinical outcomes were significantly improved in
atients switched to bivalirudin. In patients defined as
linical Outcomes at 30 Days
Table 2 Clinical Outcomes at 30 Days
Consistent
UFH/Enoxaparin 
GP IIb/IIIa
Inhibitor
(n  2,137)
Switch
Bivalirudin
(n  2,078) RR 95% CI
Composite ischemia 159 (7.4%) 144 (6.9%) 0.93 0.75–1.1
Death 27 (1.3%) 21 (1.0%) 0.80 0.45–1.4
MI 117 (5.5%) 100 (4.8%) 0.88 0.68–1.1
Unplanned
revascularization
37 (1.7%) 47 (2.3%) 1.31 0.85–2.0
Major bleeding 124 (5.8%) 59 (2.8%) 0.49 0.36–0.6
Transfusion 55 (2.6%) 32 (1.5%) 0.60 0.39–0.9
Net clinical outcome 255 (11.9%) 191 (9.2%) 0.77 0.65–0.9
High Risk* (n  1,581) (n  1,496)
Ischemic composite 129 (8.2%) 115 (7.7%) 0.94 0.74–1.2
Death 26 (1.6%) 20 (1.3%) 0.81 0.46–1.4
MI 97 (6.1%) 84 (5.6%) 0.92 0.69–1.2
Unplanned
revascularization
25 (1.6%) 33 (2.2%) 1.40 0.83–2.3
Major bleeding 103 (6.5%) 53 (3.5%) 0.54 0.39–0.7
Transfusion 47 (3.0%) 30 (2.0%) 0.67 0.43–1.0
Net clinical outcome 206 (13.0%) 159 (10.6%) 0.82 0.67–0.9
PCI (n  1,236) (n  1,292)
Ischemic composite 101 (8.2%) 116 (9.0%) 1.10 0.85–1.4
Death 8 (0.6%) 13 (1.0%) 1.55 0.65–3.7
MI 78 (6.3%) 84 (6.5%) 1.03 0.76–1.3
Unplanned
revascularization
30 (2.4%) 39 (3.0%) 1.24 0.78–1.9
Major bleeding 83 (6.7%) 45 (3.5%) 0.52 0.36–0.7
Transfusion 35 (2.8%) 23 (1.8%) 0.63 0.37–1.0
Net clinical outcome 163 (13.2%) 153 (11.8%) 0.90 0.73–1.1High risk  elevated cardiac biomarkers or ST-segment deviation 1 mm.
CI  confidence interval; RR  relative risk; other abbreviations as in Table 1.igh risk and in patients undergoing PCI, composite
schemia was similar but bleeding was significantly lower
n patients switched to bivalirudin (Table 2). These
nalyses were not affected by exclusion of potentially
verdosed patients.
atients naive before antithrombin therapy. As shown in
able 1, patients naive to antithrombin therapy randomized
o UFH/ENOX plus a GP IIb/IIIa inhibitor or to bivaliru-
in had similar baseline characteristics except there were
ore patients with a history of prior MI and prior PCI in
he bivalirudin group. Net clinical outcome and composite
schemia occurred with similar frequency in the 2 groups,
hile major bleeding was significantly lower with bivaliru-
in (Table 2, Fig. 2).
In naive antithrombin patients, there were 170 who
otentially were excessively dosed; 167 eptifibatide, 1
NOX, and 2 eptifibatide plus ENOX. The results for
schemic events and net clinical outcomes were unchanged
hen these patients were excluded from analyses. Major
leeding rates with these excluded patients were 4.5% for
he consistent UFH ENOXGP IIb/IIIa inhibitors group
ersus 2.5% for the bivalirudin group (RR 0.57, 95% CI
.38 to 0.85, p  0.006).
p
Value
Naive
UFH/Enoxaparin 
GP IIb/IIIa
Inhibitor (n  1,462)
Naive
Bivalirudin
(n  1,427) RR 95% CI
p
Value
0.52 81 (5.5%) 88 (6.2%) 1.11 0.83–1.49 0.47
0.44 12 (0.8%) 14 (1.0%) 1.20 0.55–2.58 0.65
0.33 51 (3.5%) 67 (4.7%) 1.35 0.94–1.92 0.10
0.22 35 (2.4%) 28 (2.0%) 0.82 0.50–1.34 0.43
0.01 71 (4.9%) 36 (2.5%) 0.52 0.35–0.77 0.01
0.02 35 (2.4%) 15 (1.1%) 0.44 0.24–0.80 0.01
0.01 138 (9.4%) 114 (8.0%) 0.85 0.67–1.07 0.17
(n  805) (n  818)
0.63 54 (6.7%) 62 (7.6%) 1.13 0.79–1.61 0.50
0.48 9 (1.1%) 9 (1.1%) 0.98 0.39–2.47 0.97
0.54 37 (4.6%) 50 (6.1%) 1.33 0.88–2.01 0.18
0.21 20 (2.5%) 18 (2.2%) 0.89 0.47–1.66 0.71
0.01 46 (5.7%) 25 (3.1%) 0.53 0.33–0.86 0.01
0.09 21 (2.6%) 8 (1.0%) 0.37 0.17–0.84 0.02
0.04 89 (11.1%) 80 (9.8%) 0.88 0.66–1.18 0.40
(n  808) (n  831)
0.47 54 (6.7%) 57 (6.9%) 1.03 0.72–1.47 0.89
0.32 4 (0.5%) 3 (0.4%) 0.73 0.16–3.25 0.68
0.84 35 (4.3%) 50 (6.0%) 1.39 0.91–2.12 0.13
0.36 24 (3.0%) 21 (2.5%) 0.85 0.48–1.52 0.58
0.01 47 (5.8%) 22 (2.6%) 0.46 0.28–0.75 0.01
0.08 21 (2.6%) 8 (1.0%) 0.37 0.17–0.83 0.02
0.31 91 (11.3%) 75 (9.0%) 0.80 0.60–1.07 0.136
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May 6, 2008:1734–41 Safety of Switching From Heparin to Bivalirudinomparison of outcomes in patients receiving prior
ntithrombin therapy with outcomes for antithrombin-
aive patients. Results of formal interaction testing indi-
ated that there was no interdependency between prior
ntithrombin therapy, randomized treatment assignment,
nd outcome. The interaction p values for patients random-
zed to bivalirudin or UFH/ENOX plus a GP IIb/IIIa
nhibitor and prior antithrombin therapy were not signifi-
ant (composite ischemia, p  0.34; non-CABG major
leeding, p  0.80; net clinical outcomes, p  0.51).
Figure 2 Outcomes of Patients Switched
Comparison of patients randomized to bivalirudin versus UFH/Enox by prior
antithrombin therapy. CI  confidence interval; RR  relative risk; other abbre-
viations as in Figure 1.
linical Outcomes at 30 Days According to Consistent Therapy on
Table 3 Clinical Outcomes at 30 Days According to Consistent
Consistent UFH 
GP IIb/IIIa Inhibitor
(n  1,294)
Swit
(
Composite ischemia 99 (7.7%)
Major bleeding 82 (6.3%)
Transfusion 36 (2.8%)
Net clinical outcome 162 (12.5%) 1
Randomized to UFH 
GP IIb/IIIa Inhibitor
(n  620)
Random
(
Composite ischemia 32 (5.2%)
Major bleeding 29 (4.7%)
Transfusion 16 (2.6%)
Net clinical outcome 57 (9.2%) 1bbreviations as in Tables 1 and 2.omparisons of consistent therapy with UFH and consis-
ent therapy with ENOX to switch to bivalirudin. Tables 3
nd 4 show clinical outcomes according to type of heparin
herapy (UFH or ENOX) in patients on prior antithrombin
herapy and in patients naive to antithrombin therapy. In
atients switched from either UFH or ENOX to bivaliru-
in, there were similar rates of composite ischemia and
ignificant reductions in major bleeding; in patients naive to
ntithrombin therapy, there were similar rates of composite
schemia and significant reductions in major bleeding for
hose randomized to bivalirudin versus either UFH or
NOX plus a GP IIb/IIIa inhibitor.
iscussion
his analysis demonstrates that patients with moderate-
nd high-risk acute coronary syndromes in whom an inva-
ive strategy is planned can be safely switched from UFH or
NOX to bivalirudin monotherapy before angiography.
his approach results in an approximate 50% reduction in
ajor bleeding with similar rates of ischemia as compared
ith consistent therapy with UFH or ENOX plus a GP
Ib/IIIa inhibitor. These findings are consistent with the
verall results from the ACUITY trial. The demonstration
hat net clinical outcomes are improved by switching pa-
ients pre-treated with UFH or ENOX to bivalirudin is
linically relevant, since moderate and high-risk NSTE-
CS patients are often treated with either UFH or ENOX
n the emergency department or at a transferring hospital
efore treatment with bivalirudin. Also, the recent Euro-
ean Society of Cardiology guidelines for the diagnosis and
reatment of NSTE-ACS recommend that for PCI proce-
ures the initial anticoagulant should be maintained during
he procedure regardless of whether this treatment is UFH,
NOX, or bivalirudin (6).
The SYNERGY trial demonstrated that crossing over to
n alternate heparin is associated with increased bleeding
Versus Switch From UFH to Bivalirudin
apy on UFH Versus Switch From UFH to Bivalirudin
Prior Antithrombin Therapy
alirudin
313) RR 95% CI p Value
.4%) 0.97 0.74–1.26 0.80
.8%) 0.44 0.30–0.65 0.01
.8%) 0.63 0.38–1.06 0.08
.4%) 0.75 0.60–0.93 0.01
aive to Antithrombin Therapy
Bivalirudin
427)
.2%) 1.19 0.81–1.77 0.38
.5%) 0.54 0.33–0.87 0.01
.1%) 0.41 0.20–0.82 0.01
.0%) 0.87 0.64–1.18 0.36UFH
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ch Biv
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herapies on top of one another without a sufficient washout
eriod, although the possibility of a chance spurious finding
annot be excluded. Algorithms for switching from UFH or
NOX to the alternate heparin have not been validated.
The results of the present analysis are consistent with
revious data. A recent open-label trial analyzed 91 NSTE-
CS patients who had previously received 1 dose of
NOX (1 mg/kg) within 12 h before PCI and were
ubsequently administered bivalirudin (0.75 mg/kg bolus
nd 1.75 mg/kg/h) at the time of PCI. Rates of bleeding
nd ischemic events were similar in groups defined by the
nterval between the last dose of ENOX and bivalirudin
dministration (13). In the REPLACE-2 (Randomized
valuation of PCI Linking Angiomax to Reduced Clinical
vents) trial, among patients randomized to receive biva-
irudin, there was no difference in major bleeding between
atients receiving prior UFH (n  287) or ENOX (n 
58) and patients not receiving prior antithrombin therapy
n 2,345). Cumulative distribution curves suggest that the
uration of time between discontinuation of UFH or
NOX did not affect bleeding rates (14).
The safety and efficacy of switching from prior UFH or
NOX to bivalirudin may be partly explained by the
echanism of action of the antithrombin agents. Bivaliru-
in directly targets thrombin, specifically inhibits both clot
ound and fluid phase thrombin and has a short half-life of
pproximately 25 min. Bivalirudin becomes biologically
nactive when it is cleaved by thrombin and then dissociates,
llowing thrombin to return to normal hemostatic activity
15). In contrast, UFH and ENOX are nonspecific, indirect
hrombin inhibitors with relatively longer half-lives. Com-
ining 2 agents such as UFH and ENOX may lead to
xcessive bleeding due to the additive effect of 2 agents with
rolonged anti Xa activity. Adding bivalirudin with its lack
linical Outcomes at 30 Days According to Consistentherapy on Enoxap rin Versu Switch From Enoxaparin to Bivalirud
Table 4 Clinical Outcomes at 30 Days According to ConsistentTherapy on Enoxaparin Versus Switch From Enoxaparin
Consistent Enoxaparin
 GP IIb/IIIa Inhibitor
(n  843)
S
Composite ischemia 60 (7.1%)
Major bleeding 42 (5.0%)
Transfusion 19 (2.3%)
Net clinical outcome 93 (11.0%)
Randomized to Enoxaparin
 GP IIb/IIIa Inhibitor
(n  842)
Rand
Composite ischemia 49 (5.8%)
Major bleeding 42 (5.0%)
Transfusion 19 (2.3%)
Net clinical outcome 81 (9.6%)
bbreviations as in Tables 1 and 2.f Xa activity to UFH or ENOX would not increase the Axisting anti-Xa activity, and any incremental anti-IIa effect
ould be temporary given its short half-life and rapid
learance.
tudy strengths and limitations. The strength of the
resent analysis is that switching took place through
rotocol-mandated randomization and was not determined
y investigator preference or the occurrence of either bleed-
ng or ischemic events. Also, baseline characteristics of
atients on consistent UFH or ENOX therapy were well
alanced with those of patients switched to bivalirudin
onotherapy. However, our analysis was post hoc, and
re-randomization use of antithrombin therapy was not
tratified.
onclusions
n patients with moderate- and high-risk NSTE-ACS, this
nalysis suggests that switching from either UFH or ENOX
o bivalirudin monotherapy before angiography results in a
imilar rate of composite ischemia compared with consistent
reatment with UFH or ENOX plus a GP IIb/IIIa inhib-
tor. Further, our data suggest that switching to bivalirudin
onotherapy may result in an approximate 50% reduction
n major bleeding compared with remaining on either UFH
r ENOX. Patients naive to antithrombin therapy who were
dministered bivalirudin monotherapy had a significant
eduction in major bleeding with similar rates of composite
schemia compared with patients administered UFH or
NOX plus a GP IIb/IIIa inhibitor.
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